Indian Long-Acting Bronchodilator Market Size, Industry Trends, Share and Forecast 2019-2025.


Posted February 25, 2020 by mansi3210

Indian Long-Acting Bronchodilator Market Size, Share & Trends Analysis Report by Route of Administration , by Application , by End-User and Forecast 2019-2025

 
Indian long-acting bronchodilator market is anticipated to grow at a substantial rate of around 8.0% during the forecast period. Major factors that augments the growth of the market include large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and significant presence of market players in the country. The Indian long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parental, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the increasing pool of aging population susceptible to the high prevalence of asthma in the country.
Request a Free Sample of our Report Indian Long-Acting Bronchodilator Market: https://www.omrglobal.com/request-sample/indian-long-acting-bronchodilator-market
Cipla is one of the major companies working in the long-acting bronchodilator market. The company offers products in the field of asthma, COPD, Allergic Rhinitis (AR), Pulmonary Arterial Hypertension (PAH), lung cancer and Idiopathic Pulmonary Fibrosis (IPF). In May 2018, the company established a partnership with ManKind for marketing and distributing Afrezza. It is the only US FDA approved inhaled insulin available for patients suffering from diabetes. In addition, the company in February 2018, has entered into a partnership with Roche Pharma India for healthcare improvement and increasing access to life-changing medicines in India.
A full Report of Indian Long-Acting Bronchodilator Market is Available at: https://www.omrglobal.com/industry-reports/indian-long-acting-bronchodilator-market
Indian Long-Acting Bronchodilator Market Segmentation
By Route of Administration
• Oral
• Nasal
• Parental
• Inhalation
By Application
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
By End-User
• Homecare
• Hospitals and Clinics
Company Profiles
• Adamis Pharmaceuticals Corp.
• AstraZeneca PLC
• Beximo Pharmaceuticals Ltd.
• Boehringer Ingelheim International GmbH
• Cipla Ltd.
• GlaxoSmithKline PLC
• Novartis AG
• ResMed Corp.
• Pulmatrix Inc.
• Sunovion Pharmaceuticals
• Teijin Pharma Ltd.
• Teva Pharmaceuticals Industries Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/indian-long-acting-bronchodilator-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit Orion Market Research
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Mansi Jain
Phone 06467557667
Business Address Indore, india
Country India
Categories Business , Food , News
Tags Indian Long-Acting Bronchodilator Market Share , Indian Long-Acting Bronchodilator Market Analysis , Indian Long-Acting Bronchodilator Market Trends , Indian Long-Acting Bronchodilator Market Forecast
Last Updated February 25, 2020